Model-Based Meta-Analysis (MBMA) Archives

Publication

The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement

This article explores the overlooked yet critical role of early strategic planning for payer reimbursement…

CertaraFebruary 25, 2025

Fact Sheet

Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA)

Whether you’re optimizing trial design or seeking strategic insights, Certara’s MBMA delivers the clarity and…

CertaraFebruary 19, 2025

On-Demand Webinar

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…

CertaraJanuary 9, 2025

Publication

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…

CertaraJanuary 8, 2025

Poster

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

CertaraDecember 11, 2024

Case Study

Using MBMA to run virtual “head-to-head trials”

Osteoporosis is common in post-menopausal women. The long-term sequelae of osteoporosis include bone fractures, particularly…

CertaraApril 21, 2023

Blog

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…

CertaraDecember 15, 2021

Blog

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…

CertaraDecember 19, 2019

Publication

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…

CertaraJune 2, 2018

Publication

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

CertaraFebruary 15, 2018

Model-Based Meta-Analysis (MBMA)

The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement

Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA)

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

Using MBMA to run virtual “head-to-head trials”

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Newsletter sign up

Quick links

Solutions

Contact